Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
LFW Photonics Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Elicio Therapeutics Inc
(NQ:
ELTX
)
4.440
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
4.440
Bid (Size)
3.500 (1)
Ask (Size)
7.100 (2)
Prev. Close
4.440
Today's Range
4.440 - 4.440
52wk Range
2.960 - 11.45
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Why Is Cancer Vaccine Developer Elicio Therapeutics Stock Trading Lower On Friday?
June 28, 2024
Elicio Therapeutics announced promising preliminary data from the AMPLIFY-7P Phase 1a study of ELI-002 7P, showing extended median disease-free survival in patients with mKRAS-driven solid tumors.
Via
Benzinga
Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering
June 28, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Performance
YTD
-25.13%
-25.13%
1 Month
-37.55%
-37.55%
3 Month
-46.05%
-46.05%
6 Month
-9.20%
-9.20%
1 Year
-57.79%
-57.79%
More News
Read More
Why Is Elicio Therapeutics (ELTX) Stock Down 36% Today?
June 28, 2024
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
June 28, 2024
Via
InvestorPlace
First Patient Dosed In Phase 2 Study Of Elicio Therapeutics’ ELI-002 7P
February 01, 2024
Via
News Direct
Elicio Therapeutics Announces Proposed Public Offering
June 27, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P
June 27, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Elicio Therapeutics Unveils Promising Phase 1a Data For ELI-002 7P In mKRAS Tumors
June 10, 2024
Via
News Direct
12 Health Care Stocks Moving In Thursday's Intraday Session
May 16, 2024
Via
Benzinga
ELTX Stock Earnings: Elicio Therapeutics Beats EPS for Q1 2024
May 15, 2024
Via
InvestorPlace
Elicio Therapeutics (NASDAQ: ELTX) Makes Strides In Growing Cancer Vaccination Industry
April 11, 2024
Via
News Direct
12 Health Care Stocks Moving In Friday's After-Market Session
April 05, 2024
Via
Benzinga
Unlocking the Power of Immunotherapy: Elicio Therapeutics’ (NASDAQ: ELTX) Novel AMP Platform
April 05, 2024
Via
News Direct
Topics
Death
Exposures
Death
ELTX Stock Earnings: Elicio Therapeutics Misses EPS for Q4 2023
April 02, 2024
Via
InvestorPlace
Benzinga's 2024 Virtual Healthcare: What's Next In Health?
March 19, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
March 18, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
March 18, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
February 08, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
February 07, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
February 07, 2024
Via
Benzinga
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating Power Of Amphiphile-Immunotherapy
February 06, 2024
Via
News Direct
Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 05, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Elicio Therapeutics Announces Publication Of Preclinical Data Demonstrating Power Of Amphiphile-Immunotherapy
February 05, 2024
Via
Benzinga
First Patient Dosed In Phase 2 Study Of Elicio Therapeutics' ELI-002 7P
January 31, 2024
Via
Benzinga
Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutics' AMPLIFY-201 Phase 1 Solid Tumor Study Of ELI-002
January 30, 2024
Via
News Direct
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.